Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TYMP | P19971 | 3/20 | 0.49 |
| ▸ | FFAR3 | O14843 | 1/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.46 |
| ▸ | HCAR2 | Q8TDS4 | 1/20 | 0.46 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.45 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL357910 | 0.94 | TYMP (0.50) | TYMPHCAR2ATAD2 | |
| SCHEMBL6573665 | 0.93 | TYMP (0.51) | TYMPHCAR2ATAD2 | |
| SCHEMBL156784 | 0.88 | ATAD2 (0.48) | TYMPHCAR2ATAD2 | |
| SCHEMBL4353311 | 0.83 | DPYD (0.50) | ATAD2 | |
| SCHEMBL10983716 | 0.81 | KMT2A (0.53) | TYMPFFAR3HCAR3HCAR2KDM4E | |
| SCHEMBL161148 | 0.81 | ATAD2 (0.54) | ATAD2 | |
| SCHEMBL23610067 | 0.81 | GAA (0.47) | ATAD2 | |
| SCHEMBL7599681 | 0.81 | ALDH1A1 (0.45) | ATAD2 | |
| SCHEMBL29767278 | 0.80 | HCAR2 (0.50) | HCAR2ATAD2 | |
| SCHEMBL7603360 | 0.79 | ALDH1A1 (0.44) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 598 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2024026372-A2 | HYDROGEN BONDING BOTTLEBRUSH POLYMERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-02-01 | — | — | WO | claimed |
| US-20150211004-A1 | RNAI-BASED THERAPIES FOR CARDIOMYOPATHIES, MUSCULAR DYSTROPHIES AND LAMINOPATHIES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2015-07-30 | — | — | US | claimed |
| EP-2838541-A1 | RNAI-BASED THERAPIES FOR CARDIOMYOPATHIES, MUSCULAR DYSTROPHIES AND LAMINOPATHIES | Agency For Science, Technology And Research (SG) | 2015-02-25 | — | — | EP | claimed |
| WO-2013158046-A1 | RNAI-BASED THERAPIES FOR CARDIOMYOPATHIES, MUSCULAR DYSTROPHIES AND LAMINOPATHIES | AGENCY FOR SCIENCE, TECHNOLOGY AND RESEARCH (SG) | 2013-10-24 | — | — | WO | claimed |
| EP-0637965-B1 | ENHANCED TRIPLE-HELIX AND DOUBLE-HELIX FORMATION WITH OLIGOMERS CONTAINING MODIFIED PYRIMIDINES | ISIS PHARMACEUTICALS INC (US) | 2002-10-16 | — | — | EP | claimed |
| US-12606814-B2 | Oligonucleotide probes and uses thereof | CARIS SCIENCE, INC. (US) | 2026-04-21 | — | — | US | disclosed |
| US-20260078383-A1 | RNA NANOSTRUCTURES AND METHODS OF MAKING AND USING RNA NANOSTRUCTURES | UNIV ARIZONA STATE (US) | 2026-03-19 | — | — | US | disclosed |
| US-12577627-B2 | Selective detection of different dengue virus RNA serotypes using tandem toehold-mediated displacement reactions | ARIZONA BOARD OF REGENTS ON BEHALF OF ARIZONE STATE UNIVERSITY (US) | 2026-03-17 | — | — | US | disclosed |
| US-20260041702-A1 | AGENTS THAT INHIBIT CCN LIGAND-INDUCED SIGNALLING FOR TREATING DISEASE | TRIBUNE THERAPEUTICS AB (SE) | 2026-02-12 | — | — | US | disclosed |
| EP-4683716-A1 | DNA NANODEVICES FOR SPECIFIC AND EFFICIENT DELIVERY OF FUNCTIONAL PAYLOADS TO THE CYTOPLASM AND METHODS OF THEIR USE | Arizona Board of Regents on behalf of Arizona State University (US) | 2026-01-28 | — | — | EP | disclosed |
| EP-4680212-A1 | ADAR1 INHIBITORS FOR TREATING CANCER | Institute of Cancer Research Royal Cancer Hospital (GB) | 2026-01-21 | — | — | EP | disclosed |
| US-20260014278-A1 | HYBRID PEPTIDE DENDRIMER SYSTEMS AND EXTRAHEPATIC DELIVERY | NUNTIUS THERAPEUTICS LTD (GB) | 2026-01-15 | — | — | US | disclosed |
| EP-0515464-B1 | PROCESS FOR PREPARING URACIL DERIVATIVES | ERBA CARLO SPA (IT) | 1994-10-19 | — | — | EP | disclosed |
| US-5286861-A | Process for preparing uracil derivatives | FARMITALIA CARLO ERBA S.R.L. (IT) | 1994-02-15 | — | — | US | disclosed |
| EP-0572529-A1 | APTAMER SPECIFIC FOR BIOMOLECULES AND METHOD OF MAKING | GILEAD SCIENCES, INC. (US) | 1993-12-08 | — | — | EP | disclosed |
| WO-1992014842-A1 | APTAMERS SPECIFIC FOR THROMBIN AND METHODS OF USE | GILEAD SCIENCES, INC. (US) | 1992-09-03 | — | — | WO | disclosed |
| WO-1992014843-A1 | APTAMER SPECIFIC FOR BIOMOLECULES AND METHOD OF MAKING | GILEAD SCIENCES, INC. (US) | 1992-09-03 | — | — | WO | disclosed |
| WO-1991013064-A1 | PROCESS FOR PREPARING URACIL DERIVATIVES | FARMITALIA CARLO ERBA S.R.L. (IT) | 1991-09-05 | — | — | WO | disclosed |
| US-4182859-A | Process for the preparation of 2'-deoxyribofuranosyl nucleosides | ROBUGEN GMBH PHARMACEUTISCHE FABRIK (DE) | 1980-01-08 | — | — | US | disclosed |
| US-3935184-A | Synthetic polyoxin type nucleosides | SYNTEX (U.S.A.) INC. (US) | 1976-01-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12577627-B2 | Selective detection of different dengue virus RNA serotypes using tandem toehold-mediated displacement reactions | DDX41, DDX5, DDX6 | TYMP 2886/4885FFAR3 3231/4885HCAR3 3638/4885 |
| US-12606814-B2 | Oligonucleotide probes and uses thereof | CD63, FLT4, NCL | TYMP 814/4885FFAR3 1842/4885HCAR3 4329/4885 |
| US-20260041702-A1 | AGENTS THAT INHIBIT CCN LIGAND-INDUCED SIGNALLING FOR TREATING DISEASE | PKD2, CCNK, PKD1 | TYMP 1238/4885FFAR3 2644/4885HCAR3 3924/4885 |
| US-20260078383-A1 | RNA NANOSTRUCTURES AND METHODS OF MAKING AND USING RNA NANOSTRUCTURES | PDCD1, TIA1, NSUN2 | TYMP 2547/4885FFAR3 3610/4885HCAR3 3994/4885 |
| US-20260014278-A1 | HYBRID PEPTIDE DENDRIMER SYSTEMS AND EXTRAHEPATIC DELIVERY | CD47, CD2BP2, CD40LG | TYMP 1157/4885FFAR3 1039/4885HCAR3 2616/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.